Sign In
Buy RVMD
$155.99
+4.68 (+3.09%)
At Close: Jun 03, 2026
Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates
06:21pm, Monday, 26'th Feb 2024
Revolution Medicines, Inc. (RVMD) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to loss of $0.63 per share a year ago.
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
04:05pm, Monday, 26'th Feb 2024
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
04:05pm, Tuesday, 20'th Feb 2024
REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today
Revolution Medicines to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 01'st Feb 2024
REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today annou
Wall Street Analysts See a 27.5% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High?
11:11am, Wednesday, 17'th Jan 2024
The mean of analysts' price targets for Revolution Medicines, Inc. (RVMD) points to a 27.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agree
Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
07:00am, Thursday, 04'th Jan 2024
REDWOOD CITY, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today annou
Pharma's Frontline: 3 Stocks Driving Revolutionary Drug Development
05:04pm, Friday, 15'th Dec 2023
The pharma stock leaders can at times seem overly risk averse with their approach to developing new medicines and cures. With the difficulty of clinical trials and the uncertainty of Federal Drug Adm
3 Biotech Stocks That Could Boom or Bust by 2025
05:35pm, Thursday, 16'th Nov 2023
InvestorPlace published an article last December about the seven hottest biotech stocks to own in 2023 and beyond. One of the seven was the SPDR S&P Biotech ETF (NYSEARCA: XBI ).
Revolution Medicines Completes Acquisition of EQRx
09:10am, Thursday, 09'th Nov 2023
Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines' Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs
Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition
11:30am, Wednesday, 08'th Nov 2023
REDWOOD CITY, Calif. and CAMBRIDGE, Mass.
Revolution Medicines, Inc. (RVMD) Q3 2023 Earnings Conference Call Transcript
08:04pm, Monday, 06'th Nov 2023
Revolution Medicines, Inc. (NASDAQ:RVMD ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Erin Graves - Senior Director of Corporate Communications and IR Mark Goldsm
Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Lags Revenue Estimates
07:34pm, Monday, 06'th Nov 2023
Revolution Medicines, Inc. (RVMD) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $1.01. This compares to loss of $0.87 per share a year ago.
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
04:05pm, Monday, 06'th Nov 2023
Promising clinical data for RMC-6236, a RAS MULTI (ON) Inhibitor, and RMC-6291, a RAS G12C (ON) Inhibitor, presented at AACR-NCI-EORTC (“Triple”) and ESMO Meetings
Revolution Medicines Also Announces the Final Exchange Ratio of 0.1112 Revolution Medicines Also Announces the Final Exchange Ratio of 0.1112
Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023
04:15pm, Tuesday, 31'st Oct 2023
REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today
